1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 Diabetes Mellitus

Publication date: Available online 2 August 2020Source: Journal of Clinical &Translational EndocrinologyAuthor(s): Masahiro Usui, Mamiko Tanaka, Hironori Takahashi
Source: Journal of Clinical and Translational Endocrinology - Category: Endocrinology Source Type: research

Related Links:

Publication date: Available online 25 September 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Gyu Sik Choi, Hye Sook Min, Jin Joo Cha, Ji Eun Lee, Jung Yeon Ghee, Ji Ae Yoo, Ki Tae Kim, Young Sun Kang, Sang Youb Han, Yun Soo Bae, Sae Rom Lee, Jung Yeon Yoo, Sung Hwan Moon, Soo Jin Lee, Dae Ryong Cha
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Conclusions: ABL is an effective and well-tolerated treatment for women with postmenopausal osteoporosis at high risk for fracture. Its therapeutic effects are sustained with subsequent ALN therapy. PMID: 32969719 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
This study aims to explore gender differences between T2DM and employment status. Data from the Korea Health Panel Study, 2013–2015 were analyzed by distinguishingT2DM and non-diabetes (N = 11,216). The empirical model was established and the generalized two-stage least squares (2SLS) was estimated, controlling for endogeneity. A family history of diabetes, as an instrumental variable, was related to an individual’s genetic predisposition to develop diabetes. The estimated results for the 2SLS showed the interaction effects between T2DM and employment. T2DM had a statistically significant and negative e...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: HSK7653 10 mg Q2W;   Drug: HSK7653 25 mg Q2W;   Drug: Linagliptin 5 mg QD Sponsor:   Sichuan Haisco Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: ORMD-0801;   Other: Placebo Sponsor:   Oramed, Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: HSK7653 10 mg Q2W;   Drug: HSK7653 25 mg Q2W;   Drug: Linagliptin 5 mg QD Sponsor:   Sichuan Haisco Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: ORMD-0801;   Other: Placebo Sponsor:   Oramed, Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
FRIDAY, Sept. 25, 2020 -- Rheumatoid arthritis (RA) is associated with an increased risk for diabetes mellitus (DM) incidence, according to research presented at the annual meeting of the European Association for the Study of Diabetes, held...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noni...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
Peripheral artery disease (PAD) represents one of the most relevant vascular complications of type 2 diabetes mellitus (T2DM). Moreover, T2DM patients suffering from PAD have an increased risk of major adverse...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Japan Health | Sodium